Having made some solid capital gains from various ophthalmology and niche med-tech companies in the past, I looked into Synergetics (NASDAQ:SURG) hoping to find an interesting growth opportunity that the Street has simply not caught on to yet. While I did find a decent company with some growth and capital appreciation potential, the magnitude of that potential was maybe not quite what I was hoping to find. Though I intend to monitor this company in the future to see whether they can capitalize on any disruptions at Valeant's (NYSE:VRX) Bausch + Lomb business, I'm not sure I see quite enough opportunity today to merit a strong recommendation.
Taking On A Giant With Dexterity And Customer...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|